Skip to main content
. 2005 Sep 6;102(37):13230–13235. doi: 10.1073/pnas.0505070102

Fig. 4.

Fig. 4.

Allograft survival in CD4- and CD8-deficient mice treated with combination therapy. C57BL/6 CD4 (A) and CD8 (B) KO recipients were treated with DST/anti-CD45/anti-CD154. (A) Untreated graft survival in CD4 KO recipients was nominally prolonged compared with WT recipients (MST = 12.5 vs. 11 d; P = 0.007). However, WT recipients exhibit significantly better long-term graft survival (>120 d) than CD4 KO recipients after combination therapy (P = 0.035). (B) Treated CD8 KO mice exhibited prolonged engraftment (MST = 92 vs. 9 d for untreated CD8 KO controls; P < 0.005). However, WT recipients exhibit significantly better graft survival than CD8 KO recipients after combination therapy (P = 0.0003).